Tesamorelin Research FAQ — Purity, Legality & Sourcing in the UAE (2026)

What Is Tesamorelin?

Tesamorelin is a 44-amino-acid GHRH (growth-hormone-releasing hormone) analogue with a molecular weight of approximately 5135 Da. It is the active ingredient in an FDA-approved pharmaceutical (brand name Egrifta) for a specific HIV-associated lipodystrophy indication, studied by Falutz and colleagues in trials published in journals including NEJM and JCEM. REVIVE LAB UAE supplies research-grade tesamorelin as a separate laboratory reference product — not the approved pharmaceutical. For mechanism detail, see our mechanism of action research article; for trial and pharmaceutical-history context, see our clinical trial literature review.

Sourcing and Purity Questions

How does REVIVE verify tesamorelin purity?

Every batch is independently tested by HPLC (high-performance liquid chromatography), the standard analytical method for peptide purity verification in research supply chains. REVIVE's tesamorelin is verified at ≥98.5% purity, and each vial ships with a certificate of analysis (COA) documenting batch number, manufacture date and the HPLC purity result.

What comes in the box?

A 10 mg lyophilised (freeze-dried) powder vial, sealed and desiccated for stability, accompanied by the COA and clear Research Use Only labelling.

Can I request the raw COA data before ordering?

Yes — research buyers and institutional labs can request batch-specific COA documentation. This is standard practice for any laboratory sourcing decision and REVIVE supports it as part of transparent research supply.

Legal and Regulatory Questions

Is it legal to buy research peptides like tesamorelin in the UAE?

REVIVE LAB UAE operates as a B2B supplier of laboratory research reference materials to research institutions, laboratories and qualified research buyers across the UAE. Every product is sold strictly for research use and labelled accordingly. Buyers are responsible for ensuring their own institutional and regulatory compliance under applicable UAE law — this FAQ is not legal advice, and research buyers with specific compliance questions should consult their institution's regulatory affairs office.

Is REVIVE's tesamorelin the same as the FDA-approved drug Egrifta?

No. Egrifta is an FDA-approved pharmaceutical for a specific HIV-associated lipodystrophy indication, distributed through pharmaceutical channels. REVIVE supplies research-grade tesamorelin as a laboratory research reference material through a separate distribution channel — it is not sold as, marketed as, or intended as a substitute for Egrifta or any approved drug product.

Does REVIVE ship internationally or only within the UAE?

REVIVE LAB UAE's cold-chain logistics network is built around UAE-wide delivery — Dubai, Abu Dhabi, Sharjah and the Northern Emirates. See the product page for current shipping coverage.

Storage and Handling Questions

How should the vial be stored?

Lyophilised tesamorelin should be kept desiccated at −20°C until laboratory use. This is general storage guidance for maintaining compound stability, not usage instructions.

How is the powder reconstituted for laboratory work?

Standard laboratory practice is to reconstitute the lyophilised powder with bacteriostatic water — typically 3–5 mL for a 10 mg vial — to bring it into solution for research handling. This describes lab preparation only; REVIVE does not provide dosing or administration guidance.

Does REVIVE answer dosing questions?

No. REVIVE does not provide dosing, administration frequency, or any usage instructions for tesamorelin or any other product. All compounds sold by REVIVE LAB UAE are Research Use Only, and researchers should follow their own institution's protocols and applicable regulatory guidance for any laboratory work.

Tesamorelin Vial Reference Table